Tempest Therapeutics, Inc. (TPST) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on August 12, 2021, by Tempest Therapeutics, Inc., a Delaware corporation. The filing primarily serves to announce the Company's financial results for the second fiscal quarter ended June 30, 2021, and to report the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text references a press release (Exhibit 99.1) containing the specific financial results for the second quarter of 2021. However, the body of this 8-K filing does not explicitly state numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for these specific figures.
Material Changes and Corporate Actions
- Board Appointment: Effective August 6, 2021, the Board appointed Ronit Simantov, M.D., as a Class III director. Her term will last until the 2024 annual meeting of stockholders.
- Director Compensation: Dr. Simantov will receive an annual cash compensation of $40,000.
- Equity Grants:
- Initial grant: Option to purchase 6,635 shares of common stock. Vesting schedule: 1/3 on the one-year anniversary of the grant date, with the remaining 2/3 vesting in equal monthly installments over the subsequent 24 months.
- Annual grants: Option to purchase 3,318 shares following each annual meeting starting in 2022. These vest 100% on the earlier of the one-year anniversary of the grant or the subsequent year's annual meeting.
Guidance, Outlook, and Risks
The filing incorporates by reference a press release titled "Tempest Reports Second Quarter 2021 Financial Results and Provides Corporate Highlights." The 8-K text itself does not contain specific management commentary, forward-looking guidance, risk factors, or details on contingencies beyond the standard incorporation of the press release.
Key Facts for Investor Verification
- Verify the specific Q2 2021 financial metrics (revenue, net loss, cash position) in the attached Exhibit 99.1 press release, as they are not detailed in the 8-K text.
- Confirm the impact of the new director appointment on the Board's composition and expertise.
- Review the dilution impact of the stock options granted to Dr. Simantov (6,635 initial shares plus potential future grants).
- Check the Company's cash runway and burn rate as disclosed in the referenced press release to assess liquidity needs.